Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity

Bernard Thébaud

doi:10.1055/s-0038-1639371

American Journal of Perinatology, Table of Contents

Am J Perinatol 2018; 35(06): 566-569
DOI: 10.1055/s-0038-1639371

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mesenchymal Stromal Cell Therapy for Respiratory Complications of Extreme Prematurity

Bernard Thébaud

¹Sinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

²Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada

³Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada

⁴Division of Neonatology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

› Author Affiliations

Abstract

Bronchopulmonary dysplasia remains the main complication of extreme preterm birth. Research over the past 10 years suggests the potential for stem cell-based therapies to prevent and/or restore organ damage in extreme preterm infants. Mesenchymal stromal cells, in particular, have advanced as the forerunner among various cell therapies based on very promising preclinical studies in animal models of neonatal lung injury. Early phase clinical trials are now underway to determine the safety and feasibility of this cell therapy in preterm infants at risk of developing bronchopulmonary dysplasia. This review will summarize the current rationale for testing mesenchymal stromal cells in this patient population and highlight the gaps in our knowledge to safely harness the full repair potential of cell-based therapies.

Keywords

lung - injury - stem cells - regenerative medicine - preterm birth

Full Text

References

References
1 Stoll BJ, Hansen NI, Bell EF. , et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
2 Owen LS, Manley BJ, Davis PG, Doyle LW. The evolution of modern respiratory care for preterm infants. Lancet 2017; 389 (10079): 1649-1659
3 Collaco JM, McGrath-Morrow SA. Respiratory phenotypes for preterm infants, children, and adults: bronchopulmonary dysplasia and more. Ann Am Thorac Soc 2018;
4 McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res 1960; 13: 115-125
5 Barkauskas CE, Cronce MJ, Rackley CR. , et al. Type 2 alveolar cells are stem cells in adult lung. J Clin Invest 2013; 123 (07) 3025-3036
6 Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014; 507 (7491): 190-194
7 Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol 1976; 4 (05) 267-274
8 Wagner DE, Cardoso WV, Gilpin SE. , et al; ATS Subcommittee on Stem Cells and Cell Therapies. An Official American Thoracic Society Workshop report 2015: stem cells and cell therapies in lung biology and diseases. Ann Am Thorac Soc 2016; 13 (08) S259-S278
9 Dominici M, Le Blanc K, Mueller I. , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (04) 315-317
10 Griffiths MJ, Bonnet D, Janes SM. Stem cells of the alveolar epithelium. Lancet 2005; 366 (9481): 249-260
11 Fung ME, Thébaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. Pediatr Res 2014; 75 (1-1): 2-7
12 Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011; 29 (06) 913-919
13 Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 2014; 15 (11) 1009-1016
14 Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20 (01) 14-20
15 Chang YS, Ahn SY, Jeon HB. , et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury. Am J Respir Cell Mol Biol 2014; 51 (03) 391-399
16 Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009; 106 (38) 16357-16362
17 Ambalavanan N, Morty RE. Searching for better animal models of BPD: a perspective. Am J Physiol Lung Cell Mol Physiol 2016; 311 (05) L924-L927
18 Aslam M, Baveja R, Liang OD. , et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009; 180 (11) 1122-1130
19 van Haaften T, Byrne R, Bonnet S. , et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009; 180 (11) 1131-1142
20 Augustine S, Avey MT, Harrison B. , et al. Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. Stem Cells Transl Med 2017; 6 (12) 2079-2093
21 Hsieh JY, Wang HW, Chang SJ. , et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 2013; 8 (08) e72604
22 Jin HJ, Bae YK, Kim M. , et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013; 14 (09) 17986-18001
23 Yannarelli G, Dayan V, Pacienza N, Lee CJ, Medin J, Keating A. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. Cell Transplant 2013; 22 (09) 1651-1666
24 Chang YS, Choi SJ, Ahn SY. , et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One 2013; 8 (01) e52419
25 Pierro M, Ionescu L, Montemurro T. , et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax 2013; 68 (05) 475-484
26 Chang YS, Ahn SY, Yoo HS. , et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 2014; 164 (05) 966-972
27 Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-year follow-up outcomes of premature infants enrolled in the phase i trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. J Pediatr 2017; 185: 49-54
28 Pierro M, Thébaud B, Soll R. Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017; 11: CD011932
29 Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev 2012; 21 (15) 2789-2797
30 Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol 2015; 77: 13-27
31 Willis GR, Fernandez-Gonzalez A, Anastas J. , et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med 2018; 197 (01) 104-116
32 Martin I, De Boer J, Sensebe L. ; MSC Committee of the International Society for Cellular Therapy. A relativity concept in mesenchymal stromal cell manufacturing. Cytotherapy 2016; 18 (05) 613-620
33 Chinnadurai R, Copland IB, Garcia MA. , et al. Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells 2016; 34 (09) 2429-2442
34 Galipeau J, Krampera M, Barrett J. , et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2016; 18 (02) 151-159
35 Boregowda SV, Krishnappa V, Haga CL, Ortiz LA, Phinney DG. A clinical indications prediction scale based on TWIST1 for human mesenchymal stem cells. EBioMedicine 2015; 4: 62-73
36 Zhu D, Wallace EM, Lim R. Cell-based therapies for the preterm infant. Cytotherapy 2014; 16 (12) 1614-1628
37 Alphonse RS, Vadivel A, Fung M. , et al. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014; 129 (21) 2144-2157
38 Litvack ML, Wigle TJ, Lee J. , et al. Alveolar-like stem cell-derived Myb(-) macrophages promote recovery and survival in airway disease. Am J Respir Crit Care Med 2016; 193 (11) 1219-1229
39 Monz D, Tutdibi E, Mildau C. , et al. Human umbilical cord blood mononuclear cells in a double-hit model of bronchopulmonary dysplasia in neonatal mice. PLoS One 2013; 8 (09) e74740
40 Shafa M, Ionescu LI, Vadivel A. , et al. Human induced pluripotent stem cell-derived lung progenitor and alveolar epithelial cells attenuate hyperoxia-induced lung injury. Cytotherapy 2018; 20 (01) 108-125
41 Daley GQ. Polar extremes in the clinical use of stem cells. N Engl J Med 2017; 376 (11) 1075-1077